21,058 Shares in Kymera Therapeutics, Inc. $KYMR Acquired by Jupiter Topco LLC

Key Points

• Institutional interest increased: Jupiter Topco acquired 21,058 Kymera Therapeutics shares valued at approximately $2.4 million, while several other institutions also initiated positions during the second quarter.
• Insiders sold heavily: Company insiders sold 3.59 million shares worth about $386.2 million over the past 90 days, including a $168.1 million sale by BVF Partners.
• Analysts remain optimistic: Kymera has a consensus “Moderate Buy” rating and an average price target of $128.70. Its latest quarter beat EPS expectations and generated $65 million in revenue, up 465.2% year over year.

Jupiter Topco LLC acquired a new stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 21,058 shares of the company's stock, valued at approximately $2,415,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Nicholas Investment Partners LP bought a new stake in shares of Kymera Therapeutics during the 2nd quarter valued at $6,257,000. Legal & General Group Plc bought a new position in shares of Kymera Therapeutics in the 2nd quarter worth $4,155,000. The Manufacturers Life Insurance Company bought a new position in shares of Kymera Therapeutics in the 2nd quarter worth $13,703,000. Brandywine Managers LLC acquired a new stake in shares of Kymera Therapeutics during the second quarter worth $868,000. Finally, Nan Fung Group Holdings Ltd acquired a new stake in shares of Kymera Therapeutics during the second quarter worth $3,540,436.

Insider Transactions at Kymera Therapeutics

In other Kymera Therapeutics news, Director Bruce Booth sold 31,283 shares of the business's stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $109.48, for a total transaction of $3,424,862.84. Following the sale, the director directly owned 461,794 shares of the company's stock, valued at $50,557,207.12. The trade was a 6.34% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bvf Partners L. P/Il sold 1,578,800 shares of the company's stock in a transaction dated Friday, June 26th. The stock was sold at an average price of $106.50, for a total value of $168,142,200.00. Following the sale, the director owned 240,123 shares in the company, valued at $25,573,099.50. The trade was a 86.80% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 3,587,629 shares of company stock worth $386,183,782. 15.98% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

KYMR has been the subject of a number of recent analyst reports. Oppenheimer reiterated an "outperform" rating and issued a $125.00 price objective on shares of Kymera Therapeutics in a report on Wednesday, August 5th. B. Riley Financial increased their target price on shares of Kymera Therapeutics from $117.00 to $155.00 and gave the stock a "buy" rating in a report on Monday, June 29th. Citigroup reissued a "buy" rating on shares of Kymera Therapeutics in a research report on Thursday, August 6th. Barclays boosted their price target on shares of Kymera Therapeutics from $133.00 to $139.00 and gave the company an "overweight" rating in a report on Thursday, August 6th. Finally, BTIG Research reiterated a "buy" rating and set a $134.00 target price on shares of Kymera Therapeutics in a report on Thursday, June 25th. One analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $128.70.

Kymera Therapeutics Stock Down 0.4%

Shares of NASDAQ:KYMR opened at $118.63 on Thursday. The company's fifty day simple moving average is $113.96 and its 200 day simple moving average is $94.49. The firm has a market cap of $9.86 billion, a price-to-earnings ratio of -36.61 and a beta of 1.96. Kymera Therapeutics, Inc. has a 12 month low of $40.10 and a 12 month high of $130.05.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($0.62) EPS for the quarter, beating analysts' consensus estimates of ($0.71) by $0.09. The company had revenue of $65.00 million for the quarter, compared to analyst estimates of $32.78 million. Kymera Therapeutics had a negative return on equity of 21.22% and a negative net margin of 285.33%.The company's quarterly revenue was up 465.2% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.95) earnings per share. Research analysts expect that Kymera Therapeutics, Inc. will post -3.78 earnings per share for the current fiscal year.

Kymera Therapeutics Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body's natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company's proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company's pipeline emphasizes immunology and oncology.

Want to see what other hedge funds are holding KYMR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source